3C
GTHX

361 Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

361 Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.15M Sell
47,325
-7,350
-13% -$122K 0.54% 17
2020
Q1 		$603K Buy
+54,675
New +$1.02M 0.27% 198

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

361 Capital's GTHX Position: Q2 2020 in Review

361 Capital reduced its G1 Therapeutics, Inc. Common Stock (GTHX) stake by 13% in Q2 2020, selling an estimated $122K and leaving 47,325 shares worth $1.15M. The position accounts for 0.54% of the portfolio, ranked #17.

361 Capital first reported a position in GTHX in Q1 2020 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

  • 361 Capital held 47,325 shares of G1 Therapeutics, Inc. Common Stock worth $1.15M as of Q2 2020.
  • 361 Capital sold 7,350 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $122K.
  • G1 Therapeutics, Inc. Common Stock made up 0.54% of 361 Capital's portfolio in Q2 2020, its #17 holding.
  • 361 Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.